Non-Invasive Continuous Glucose Monitoring Contact Lens GlucoLens Receives FDA Approval: Diabetes Management Says Goodbye to Finger-Prick Testing

On August 15, 2028, Alphabet's life sciences company Verily announced that its GlucoLens continuous glucose monitoring contact lens has received FDA approval. The product, indistinguishable from ordinary contact lenses, contains a miniature glucose sensor and wireless communication chip that analyzes glucose concentration in tear fluid, updating blood glucose data every five minutes.

GlucoLens's core technology is a nano-level electrochemical sensor embedded in the contact lens material. The sensor uses glucose in tear fluid reacting with specific enzymes to produce electrical signals, which are then transmitted to a paired smartphone via a micro-antenna on the lens.

In Phase III clinical trials involving 2,400 diabetes patients, GlucoLens achieved a mean absolute relative difference (MARD) of 9.2%, essentially matching the most accurate finger-prick glucose meters currently available (MARD approximately 8% to 10%). Participants reported wearing comfort was not significantly different from ordinary contact lenses.

Verily's Chief Medical Officer said GlucoLens will help the world's 500 million diabetes patients bid farewell to the pain of multiple daily finger pricks. The product is expected to launch in early 2029, with monthly costs between $50 and $80.